Drug intelligence / Profile preview

PD-32766D

Development stage: Unknown
Lead developer: PeptiDream
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

PD-32766D is a copper-64 (64Cu) labeled peptide developed by PeptiDream Inc. as part of a theranostic pair for the management of clear cell renal cell carcinoma (ccRCC). It specifically targets Carbonic Anhydrase IX (CA9), a protein highly expressed in ccRCC. PD-32766D serves as the diagnostic imaging agent, used with PET/CT scans to identify patients with high CA9 expression who may benefit from the corresponding therapeutic agent, PD-32766T (an actinium-225 labeled peptide). The drug is currently being evaluated in Phase 1 clinical trials.

Other names: 64Cu-labeled peptide targeting CA964Cu-PD-32766

Targets

CA9 (Carbonic anhydrase IX)

Beyond the preview

Go deeper on PD-32766D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD-32766D.

Explore the full profile